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Background: Focal congenital hyperinsulinism (CHI) may be cured by resection of the
focal, but often non-palpable, pancreatic lesion. The surgical challenge is to minimize
removal of normal pancreatic tissue.
Aim: To evaluate the results of intraoperative ultrasound-guided, tissue-sparing
pancreatic resection in CHI patients at an international expert center.
Methods: Retrospective study of CHI patients treated at Odense University Hospital,
Denmark, between January 2010 and March 2017.
Results: Of 62 consecutive patients with persistent CHI, 24 (39%) had focal CHI
by histology after surgery. All patients had a paternal ABCC8 or KCNJ11 mutation
and a focal lesion by 18F-DOPA-PET/CT. Intraoperative ultrasound localized the focal
lesion in 16/20 patients (sensitivity 0.80), including one ectopic lesion in the duodenal
wall. Intraoperative ultrasound showed no focal lesion in 11/11 patients with diffuse
CH (specificity 1.0). The positive predictive value for focal histology was 1.0, negative
predictive value 0.73.
Tissue-sparing pancreatic resection (focal lesion enucleation, local resection of tail or
uncinate process) was performed in 67% (n = 16). In 11/12 having tissue-sparing
resection and intraoperative ultrasound, the location of the focal lesion was exactly
identified. Eight patients had resection of the pancreatic head or head/body, four with
Roux-en-Y, three with pancreatico-gastrostomy and one without reconstruction. None
had severe complications to surgery. Cure of hypoglycaemia was seen in all patients
after one (n = 21) or two (n = 3) pancreatic resections.
Conclusion: In focal CHI, tissue-sparing pancreatic resection was possible in 67%.
Intraoperative ultrasound was a helpful supplement to the mandatory use of genetics,
preoperative 18F-DOPA-PET/CT and intraoperative frozen sections.
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INTRODUCTION
Congenital hyperinsulinism (CHI) is the most common cause of
persistent hypoglycaemia in infants with an incidence of 1–1.4
per 50,000 live births in populations without founder mutations
(1). CHI is characterized by an unregulated hypersecretion of
insulin from pancreatic beta cells despite hypoglycaemia (2, 3). A
prompt and effective treatment is necessary to avoid neurological
complications (4).
CHI is a very heterogeneous disease with respect to genetic
cause, histology and clinical presentation (5). To date, mutations
in 11 different genes are known to cause CHI, most commonly
in the beta cell KATP-channel genes ABCC8 and KCNJ11 (6). The
two major histological subtypes are focal and diffuse CHI. The
genetic basis of focal CHI is a two-hit event with a germ line
mutation in ABCC8 or KCNJ11 on the paternal allele, combined
with a focal somatic loss in pancreatic cells of the maternal
chromosome 11p15 region including ABCC8, KCNJ11 and the
maternally imprinted tumor suppressor gene p57 and hence focal
loss of heterozygosity. This causes focal adenomatous hyperplasia
of beta cells with unregulated insulin secretion due to loss of
KATP-channel function (7).
Histologically, the focal lesions preserve the normal lobular
structure of the pancreas with confluent islets of Langerhans.
The beta cells within the lesion are hyperactive, sometimes with
enlarged cytoplasm. Loss of tumor suppressor p57 staining is
characteristic within the lesion and the beta cells outside the focus
are resting with a high storage of insulin, which sometimes can be
appreciated morphologically by their smaller size (8, 9).
Until the discovery of focal CHI (10), the main treatment of
severe CHI was subtotal (95–98%) pancreatectomy to minimize
the risk of further brain damage from hypoglycaemia, but
with a recognized risk of developing insulin-dependent diabetes
(11). Thus, limited (i.e., tissue-sparing) pancreatic resection in
patients with focal CHI would represent a huge step forward
in management. Preoperative pancreatic venous sampling was
previously used to roughly identify the localisation of a focal
lesion (12). In non-palpable lesions, patients underwent piece-
meal pancreatic resections where suspicious areas from the
pancreas were submitted for frozen section until the focal
CHI lesion was identified (13). From 2006, PET/CT scan
imaging with 18F-fluoro-dihydroxyphenylalanine (18F-DOPA)
has been used as a more precise and non-invasive method
for preoperative identification and localisation of focal lesions
(14). This has helped in planning the surgical procedures.
However, the focal lesions are often only a few millimeters in
diameter, irregular in shape, may send octopus-like tentacles into
the surrounding pancreatic tissue, invisible and non-palpable
during surgery, which challenges identification and tissue-
sparing surgery. Furthermore, the surgeons find it challenging
to find a focal lesion in a three-dimensional pancreas from
a two-dimensional image. Focal lesions can be embedded
within the pancreatic tissue and may not be easily visible or
even palpable. The more recent introduction of intraoperative
ultrasound (IOUS)-guided resection has shown promising results
(15, 16).
In this preliminary study, we aimed to evaluate the
results of the surgical treatment of children with focal
CHI at an international CHI center after the introduction
of IOUS.
METHODS
Setting
In this observational study, we retrospectively evaluated
hospital files of CHI patients admitted to the International
Hyperinsulinism Centre, Hans Christian Andersen Children’s
Hospital, Odense University Hospital, Denmark, between
January 1, 2010 and March 31, 2017. Contacting the referring
medical doctors of foreign patients ensured follow-up data after
discharge.
Genetic analyses were performed by denaturing high-
performance liquid chromatography with subsequent Sanger
sequencing of ABCC8 and KCNJ11 until 2012 (17). From 2013
onwards, next generation sequencing with confirmative
Sanger sequencing of a broader panel of CHI-related
genes was used as in other institutions (18). Mutation
databases, allele frequency and in silico prediction software
programs were performed to establish the pathogenicity
of DNA variations found. Only known mutations in CHI
patients or rare mutations predicted as pathogenic were
accepted.
18F-DOPA-PET/CT scans were acquired on a GE Discovery
PET/CT scanner (GEMedical System,Waukesha,WI, USA), and
analyzed on a Dexus Advantage Workstation server 2.0 or 3.2.
An 18F-DOPA-PET/CT scan suggesting focal CHI was followed
by pancreatic surgery at our center facilities. From August
2010, IOUS was performed using a high frequency (3–15 MHz)
hockey stick transducer (L53K, Hitachi, Denmark) to aid the
localisation of the pancreatic lesions, with exclusion of patients
with intraoperative obvious palpable/visible lesions localized as
predicted by 18F DOPA-PET/CT. Patients with predicted diffuse
CHI by 18F DOPA-PET/CT were also subjected to IOUS for
control. All patients had open surgery.
Pancreatic tissue histology was assessed by intraoperative
frozen section analysis using hematoxylin-eosin staining with
the addition of immunohistochemistry for synaptophysin
in difficult cases. After surgery, the tissue specimens were
analyzed by microscopy of hematoxylin-eosin (H&E) staining
of formalin fixed, paraffin embedded 4µm thick sections;
immunohistochemical staining using the BenchMark Ultra
immunostainer (Ventana Medical Systems, Tucson, AZ) with
the OptiView-DAB detection kit (Ventana Medical Systems,
Tucson, AZ); nuclear counterstaining with the BenchMark
Ultra instrument using Hematoxylin II (Ventana Medical
Systems, Tucson, AZ) and coverslipping using a Tissue-Tek Film
coverslipper (Sakura, Alphen aan den Rijn, The Netherlands).
According to the internal protocol at the Department of
Pathology, Odense University Hospital, almost all tissue
samples had supplementary post-surgery immunohistochemical
examination, which included synaptophysin, chromogranin A,
insulin, glucagon, somatostatin, and the imprinted maternally
expressed tumor suppressor p57, for confirmation of the
diagnosis, also in cases where H&E stained slides showed the
characteristic features of focal CHI.
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Focal CHI was histologically defined as focal adenomatous
hyperplasia of beta cells as described by others (8, 9).
Patients
Inclusion criteria for the present study were a diagnosis
of hyperinsulinaemic hypoglycaemia (fasting hypoglycaemia
accompanied by inappropriately elevated plasma insulin).
Exclusion criteria were transient disease (spontaneous remission
in less than 1 month), age at onset ≥18 years and no pancreatic
surgery at Hans Christian Andersen Children’s Hospital, Odense
University Hospital, Denmark.
Patients with non-focal CHI by histology were included
regarding data on IOUS only. For the included patients with
focal CHI, the following data were recorded: Gender, age at first
symptoms, age at first recorded hypoglycaemia (0–2 days of age
<2.5 mmol/L; from 3 days of age <3.2 mmol/L), maximally
recorded glucose infusion rate (mg/kg/min), age at surgery, type
of surgery, IOUS findings, final diagnosis at histology, second
pancreatic resection (yes/no; type), admission days after surgery,
surgery time (minutes), postoperative hyperglycaemia (blood
glucose ≥7.0 mmol/l ≥24 h) or hypoglycaemia events (values),
number of days in need of intravenous (IV) glucose after surgery,
early and late postoperative complications including diabetes
(fasting blood glucose ≥7 mmol/L) and malabsorption, age at
follow-up, and follow-up time after surgery. Moreover, persistent
feeding disorder and neurological impairment (psychomotor
retardation, epilepsy, cerebral palsy, reduced vision, or hearing
loss) were recorded.
The pancreatic resections were classified according to size
and topography as larger (total/subtotal head resection or more
than 1/3 of the pancreas resected), or tissue-sparing (enucleation
or partial resection involving less than 1/3 of the pancreas).
Moreover, the difficulty of the pancreatic resection was classified
as moderate (enucleation or partial resection to the left or on the
portal vein), or high (all resections to the right of the portal vein).
Early and late postoperative complications (early:≤2 weeks; late:
>2 weeks) were graded according to Clavien-Dindo (19) and
supplemented with an evaluation of delayed gastric emptying
and pancreatic fistula according to the definitions issued by the
International Study Group for Pancreatic Surgery (20). Cure
of hypoglycaemia was defined as normal blood glucose on full
enteral eating, no i.v. glucose infusion or medication related to
hypoglycaemia at latest follow-up.
Eleven of the included patients had their cerebral outcome
described in details elswhere (21), but without data related to
surgery.
The study complied with the STROBE statement for
observational studies (22).
Statistics
Descriptive statistics included means (SD) for normally
distributed data, medians (range) for non-parametrical data
and percentages. Comparison of groups was performed using
student T test, Fischer’s exact test or Chi-square test. IBM SPSS
Statistics 24.0 was used for statistical calculations. A two-tailed
p < 0.05 was considered statistically significant; 0.05–0.10
trends.
Ethics
All patients were treated in accordance with the principles of
good clinical practice from The Declaration of Helsinki. The
Local Ethics Committee, no 56193 and Danish Data Protection
Agency, no. 16/41306, approved the study protocol. Informed
written consent was obtained from parents.
RESULTS
Patient Characteristics
Ninety-five patients were admitted to the Hans Christian
Andersen Children’s Hospital with a diagnosis of
hyperinsulinism during the study period (Figure 1). Sixty-
two patients were diagnosed with persistent CHI, of which 25
patients were excluded for being conservatively treated. None
of these patients had a diagnosis of focal CHI by 18F-DOPA-
PET/CT. Of the 37 surgically treated patients, 13 had a non-focal
(diffuse or atypical) histological diagnosis, rendering 24 resected
patients with focal CHI. The prevalence of focal CHI was 65%
among all subjected to surgery; or 39% of all with persistent CHI.
Of the 24 patients with focal CHI, three patients were
from Denmark. The other patients were referred from Russia
(n = 10), Ukraine (n = 5), and Belarus, Latvia, Georgia,
Kazakhstan, Singapore, and Sweden (n = 1 for all). Basal patient
characteristics are resumed in Table 1.
FIGURE 1 | Patient inclusion flow chart.
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TABLE 1 | Characteristics of the 24 patients with focal CHI.
GENDER, n (%)
Female 15 (63%)
Male 9 (37%)
Birth weight (grams), mean (SD), n = 20 3626 (600)
Gestational age (week), median (range), n = 20 40 (33-41)
APGAR-SCORE AT 5MIN, n (%), n = 12
Score (≥8) 8 (33%)
Score (≤7) 4 (17%)
Age at first symptoms (days), median (range), n = 23 2 (0–30)
Age at first recorded hypoglycaemia (days), median (range),
n = 23
2 (0–30)
Maximal glucose infusion rate (mg/kg/min), median (range),
n = 21
12.1 (4.4–28.3)
GENETIC MUTATION, n (%)
ABCC8 23 (96%)
KCNJ11 1 (4%)
18F-DOPA-PET/CT LOCALIZATION, n (%)
Head 11 (45.8%)
Body 4 (16.7%)
Tail 5 (20.8%)
Uncinate process 4 (16.7%)
Follow-up time after surgery (months), median (range) 12.5 (0.2–78.9)
Age at last follow-up (years), median (range) 1.7 (0.24–6.97)
All patients with focal CHI had a heterozygous paternal
KATP-channel mutation, ABCC8; n = 23 (96%), KCNJ11; n = 1
(Table 2). Five patients had novel missense mutations. Four
unrelated patients had the same mutation, ABCC8 p.Gln444His,
which we frequently have found in Russian and East European
CHI patients.
Surgery
All patients had only one focal lesion and all focal lesions (100%)
were correctly identified and roughly localized by 18F-DOPA-
PET/CT scan (Figures 2, 3). The median (range) age at surgery
was 4.8 (0.8–28.9) months (Table 3). IOUS was used together
with frozen section in 20 patients (83%), (Figure 4). In the
last four patients, the lesion was identified visually and/or by
palpation.
The IOUS identified the focal lesion correctly in 16/20
patients. In one patient, no lesion was identified by ultrasound; in
three the result was uncertain. IOUS identified non-focal disease
in 11/11 patients with diffuse histology; two diffuse patients
had no ultrasound performed. The four patients with failure of
identifying the focal lesion by IOUS either had a large pancreatic
head lesion (n = 3), or a smaller lesion in the uncinate process
(n = 1). Accordingly, IOUS had a sensitivity of 0.80, a specificity
of 1.00, a positive predictive value of 1.0 and a negative predictive
value of 0.73.
Sixteen (67%) patients had tissue-sparing pancreatic
resections. Of these, 13 patients had focal lesion enucleation with
resection of the lesion itself and less than 5% of the surrounding
normal pancreatic tissue (body or tail; n = 8, pancreatic head;
TABLE 2 | Genetics of the 24 focal CHI patients.
Patient
no.
Heterozygous paternal
KATP-channel mutations
Country of
origin
Mutation
characteristics
1 ABCC8 c.2140C>T, p.Gln714* Denmark Truncating, novel
2 ABCC8 c.1332G>T, p.Gln444His Russia Missense, prevalent
3 ABCC8 c.2866del, p.Ser956FS*86 Russia Truncating, novel
4 ABCC8 c.1332G>T, p.Gln444His Ukraine Missense, prevalent
5 ABCC8 c.4415-13G>A Ukraine Intronic
6 ABCC8 c.1332G>T, p.Gln444His Latvia Missense, prevalent
7 ABCC8 c.4309C>T, p.Arg1437* Ukraine Truncating
8 ABCC8 c.4414G>A, p.Asp1472Asn Russia Missense
9 ABCC8 c.415delC, p.Leu139fs*5 Denmark Truncating, novel
10 ABCC8 c.2921-2A>G Sweden Splice site
11 ABCC8 c.580-1G>C Denmark Splice site
12 ABCC8 c.3989-9G>A Russia Intronic, Ashkenazi
origin
13 ABCC8 c.4575+1G>C Russia Splice site novel
14 ABCC8 c.2506C>T, p.Arg836* Kazakhstan Truncating, novel
15 KCNJ11 c.998T>C, p.Phe333Ser Ukraine Missense
16 ABCC8 c.2767C>T, p.Gln923* Ukraine Truncating
17 ABCC8 c.1332G>T, p.Gln444His Russia Missense, prevalent
18 ABCC8 c.4059C>A, p.Tyr1353* Belarus Truncating
19 ABCC8 c.3557+1G>A Russia Splice site
20 ABCC8 c.4238C>T, p.Pro1413Leu Russia Missense
21 ABCC8 c.4198+1G>C Georgia Splice site
22 ABCC8 c.4477C>T, p.Arg1493Trp Russia Missense
23 ABCC8 c.4477C>T, p.Arg1493Trp Singapore Missense
24 ABCC8 c.1032C>G, p.Tyr344* Russia Truncating
n = 4, uncinate process; n = 1). The latter three patients had a
partial tail resection. The tissue-sparing resections were aided by
18F-DOPA PET/CT and IOUS in 11; by 18F-DOPA PET/CT and
intraoperative palpation and/or vision in four; and by 18F-DOPA
PET/CT with uncertain IOUS in one.
Eight patients (33%) had larger resections of the pancreatic
head (n = 6), or head/body (n = 2). Reconstruction
was performed in seven patients (Roux-en-Y pancreatico-
jejunostomy, n= 4, pancreatico-gastrostomy, n= 3). One patient
had an ectopic focal lesion, identified by 18F-DOPA-PET/CT to
be located in the pancreatic head and/or in the adjacent duodenal
wall. The lesion was neither palpable nor visible, but IOUS
together with frozen section analysis confirmed an eight-mm
lesion to be located in ectopic pancreatic tissue in the duodenal
wall,∼5mm from the major duodenal papilla (Figures 2A,B, 5).
The lesion was removed with a subtotal pancreatic head resection
combined with a small duodenotomy. Final histology confirmed
the lesion to be located in ectopic pancreatic tissue in the
duodenal wall and extending into the head of pancreas.
Three patients had a pancreatico-gastrostomy reconstruction
after resection of the pancreatic head (n = 2) or head/body
(n = 1). In two of these patients, IOUS could not localize the
focal lesion. In both patients, the pancreatic head felt firmer
than the rest of the pancreas, but the lesions could not be
visually identified. Guided by frozen section, a focal lesion was
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FIGURE 2 | 18F-DOPA-PET/CT scans of four patients with focal CHI. The focal lesions are seen in the duodenum (A,B), the pancreatic head (C,D), body (E,F), and
tail (G,H). Arrows indicate the focal lesion.
found intraoperatively in both patients (total number of frozen
sections in these patients: six and two, respectively). Both focal
lesions were relatively large, measuring 20mm and 35mm in
greatest dimension. Both patients received a resection of the
pancreatic head and part of the body. The lesion of the third
patient was located to the pancreatic head by IOUS, confirmed
by frozen section, and enucleated. During the enucleation, the
pancreatic duct was injured with leakage of pancreatic juice and
a pancreatico-gastrostomy reconstruction was performed.
Three patients had a second surgery (large pancreatic
resection with Roux-en-Y reconstruction; n = 2, partial
pancreatic body and tail resection; n = 1) after a first attempt
to perform focal lesion enucleation 1–13 days prior, but with
involvement of resection margins at histology and relapse of
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FIGURE 3 | Localisation of the focal lesions in the pancreas and duodenum
and type of surgery. The dots do not depict the lesion size. Square:
enucleation; triangle: resection of the tail or uncinate process; solid circle: large
resection.
TABLE 3 | Pancreatic surgery details in the 24 patients with focal CHI.
p-value
Age at surgery, months, median (range) 4.8 (0.8–28.9)
Intraoperative ultrasound, n (%) 20 (83%)
Hospitalization days after surgery, median (range) 10 (3–84)
Size of lesion by histology, millimeters, median (range) 8 (3–35)
Tissue sparing resection, n (%) 16 (67%)
Enucleation, n (%) 13 (81%)
Resection of tail or uncinate process, n (%) 3 (19%)
Large resection, n (%) 8 (33%)
Roux-en-Y pancreatico-jejunostomy reconstruction 4 (50%)
Pancreatico-gastrostomy reconstruction 3 (37.5%)
No reconstruction 1 (12.5%)
Difficulty of resection
Left - or on the portal vein, n (%) 10 (42%)
Right of the portal vein, n (%) 14 (58%)
Surgery time, minutes, median (range), n = 22 105 (40–255)
Left vs. right of portal vein, median minutes 92 vs. 139 0.02
Tissue sparing vs. large resection, median minutes 102 vs. 158 0.14
Patients with hypoglycaemia events after surgery, n (%) 8 (33%)
Lowest blood glucose after surgery, mmol/L, mean 2.2 (0.8)
(SD)
I.V. glucose for hypoglycaemia after surgery, days, 1 (0–8)
median (range)
Cured after 1st pancreatic operation, n (%) 21 (87.5%)
Cured after 2nd pancreatic operation, n (%) 3 (12.5%)
persistent hypoglycaemia. All patients were cured after the
second operation.
The difficulty of the pancreatic resection was classified as
moderate (to the left or on the portal vein) in 10 patients
(42%) and high (right of the portal vein) in 14 patients
(58%).
FIGURE 4 | Intraoperative ultrasound of a focal CHI lesion. A nine mm
hypo-echoic focal CHI lesion (“T”) is identified adjacent to the gastroduodenal
artery (“GDA”) and the duodenum (“Duo”).
The median (range) surgery time from incision to closure
was 105 (40–255) min. Large pancreatic resections lasted on
an average of 158 vs. 102min for tissue sparing resections,
p = 0.138. The operating time was significantly longer for
resections classified as high difficulty vs. moderate difficulty, 139
vs. 92min, p = 0.020. The median (range) hospitalization time
after surgery was 10 (3–84) days.
By histology, the focal lesions had a median (range) diameter
of eight (3–35) mm. The median number of frozen biopsies
preceding the resection per patient was two (range 1–7). In 56 out
of 57 (98%) specimens, the frozen section analysis was consistent
with the final histological diagnosis. In the one exception, the
frozen section analysis was “probably diffuse CHI” in the first
biopsy, after which the lesion was enucleated during the same
operation, however without further frozen sections. On post-
surgery analysis after formalin fixation and paraffin embedding,
the final histological analysis of the first biopsy showed normal
pancreatic tissue and the enucleated tissue showed focal CHI.
Early Postoperative Complications
Three (12%) patients had early postoperative complications. One
patient had postoperative bleeding from the stomach, which
did not need treatment (Clavien-Dindo I), one had a grade A
pancreatic fistula with a maximal drain amylase concentration
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FIGURE 5 | Histology of ectopic pancreatic tissue located in the wall of the duodenum, revealing features of focal CHI. The tissue section has been used for
intraoperative frozen section analysis prior to fixation and paraffin embedding. (A) Focal adenomatous hyperplasia, showing endocrine cells involving more than 40%
of the area (H&E staining). (B) The endocrine nature of the cells is emphasized by immunohistochemistry (synaptophysin immunostaining). (C) In the upper right
corner, the duodenal surface with mucosa containing a few Brunner’s glands is shown (Alcian blue periodic acid-Schiff staining). (D) Strong expression of CDX-2 in the
duodenal mucosa (CDX2 immunostaining).
of 1145 U/L (Clavien-Dindo I), and one had delayed gastric
emptying which was treated with an endoscopically placed
duodenal feeding tube (Clavien-Dindo IIIb).
Patients with tissue-sparing pancreatic resections had less
early postoperative complications compared to patients with
larger resections (0/16 vs. 3/8, p= 0.028). There was no difference
in early postoperative complication rates when comparing
moderate with high difficulty pancreatic resections (0/10 vs. 3/14,
p= 0.24).
Late Postoperative Complications
The median (range) follow up time after surgery was 12.5 (0.2–
78.9) months. Late postoperative complications occurred in two
patients (8%); one had an incisional hernia (Clavien-Dindo IIIb)
4 months after discharge provoked by a severe attack of epilepsy,
and one patient had small bowel obstruction from adherences
(Clavien-Dindo IIIb). Both patients were surgically treated in
their country of origin. No patients had reports of diabetes or
malabsorption.
Neurology and Other Outcomes
At last follow-up by age 1.7 (range 0.24–6.97) years, 12 (50%) had
neurological impairment, especially psychomotor retardation
(n = 12), Table 4. There was no correlation between a low
Apgar-score (p = 1.00), age at disease onset (p = 0.537), or data
TABLE 4 | Neurological impairment and other outcomes of the 24 focal CHI
patients.
n (%)
Neurological complications, total 12 (50)
Psychomotor retardation 12 (50)
Epilepsy, n = 23 5 (21)
Reduced vision 2 (8)
Cerebral palsy, n = 22 3 (13)
related to surgery and neurological impairment. Surprisingly,
a significantly lower mean (SD) maximally recorded glucose
infusion rate was seen in patients with, compared to patients
without, neurological impairment, 9.5 (3.4) vs. 15.5 (6.2)
mg/kg/min, p= 0.016.
Feeding disorder was seen in two (8%) of the patients, both
with psychomotor retardation. At last follow-up (age 7.8 months,
and 24.2 months, respectively), one had a duodenal feeding tube
and the other a gastrostomy feeding tube.
DISCUSSION
This is the first report on a cohort of CHI patients in details
describing the use of IOUS and clinical context supporting
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its use. All 24 patients were surgically treated with resultant
cure of hypoglycaemia. IOUS had a sensitivity of 0.80 and
a specificity of 1.0 in precisely localizing the focal lesion
for the surgeon. In 11/12 (92%), IOUS led to tissue-sparing
pancreatic resection with enucleation or partial resection of
the tail or uncinate process. Another four had tissue-sparing
resections after visual inspection and/or palpation only. Together,
this led to tissue-sparing resections in 16 (67%) of the
patients. The early complication rate was low and significantly
lower after tissue-sparing pancreatic resection than after larger
resections.
Our prevalence proportions of focal CHI, 39% of all with
persistent CHI and 65% of surgery-treated patients, were
comparable to other centers (5, 23, 24). Alike other centers, our
prevalences were not population-based, as many patients were
selected to referral for suspected focal CHI after genotyping. We
saw a predominance of girls (63%) as also found by some (25, 26),
but not all (27), suggesting chance findings. The median size of
the focal lesions of eight mm and a maximum of 35mm were
comparable to other studies (15, 28).
The heterozygous, paternal KATP-channel mutations
identified were predominantly ABCC8 mutations as in other
studies (27, 29). Five patients had novel mutations at the time of
investigation. Four unrelated East-European or Russian patients
had an ABCC8 mutation p.Gln444His, which we also have
frequently found in other CHI patients in these populations
suggesting a founder mutation.
The aid of IOUS to perform tissue-sparing pancreatic
resection in 11 patients represents an important improvement
in focal CHI surgery. In older studies, prior to the use of
18F-DOPA PET/CT, subtotal or near-total pancreatectomy was
predominantly used in the treatment of focal CHI (30, 31),
despite the high risk of diabetes and malabsorption after near-
total pancreatectomy (32). A French center (26) reported in 2002
of 45 children with focal CHI with more extensive pancreatic
resections, a higher number of complications, and a cure rate
of 98%, one still being hypoglycaemic after four surgeries. In
2004, the same center (33) reported on 59 infants with focal
CHI, treated with partial pancreatectomy of the tail/body, head
or isthmus based on intraoperative identification by the surgeon
and/or multiple biopsies with frozen sections. The Philadelphia
center (13) reported in 2004 of 38 focal CHI patients treated
with partial pancreatectomy. The extent of the pancreatectomies
ranged from 5 to 98%, with 37% having more than 50% of the
pancreas resected. Three patients required redo surgery due to
hypoglycaemia, of whom two were cured, making up a cure rate
of 92%. The same center reported in 2013 (1) on 138 children
surgically treated for focal CHI, guided by 18F-DOPA PET/CT in
the majority of patients, and intraoperative multiple biopsies and
frozen sections. Of the focal lesions in the pancreatic head, 39%
(23/59) were treated with near-total head resection or a Whipple
procedure. In a study reviewing patients from 1980-2008 (the
majority had no 18F-DOPA PET/CT), an average of 50% the
pancreatic tissue was resected in 54 patients with focal CHI
(34). In a recent German study with use of 18F-DOPA PET/CT
including 30 patients with focal CHI, an estimated average of 20%
of the pancreas was resected, 20% had Roux-en-Y reconstruction,
and the cure rate after one (n= 27), two (n= 2) or three (n= 1)
surgeries was 93% (28/30) (27).
Although based on retrospective data, we believe that our
extensive use of IOUS allowed tissue-sparing pancreatic resection
with the use of fewer intraoperative frozen sections, with a
comparable low reoperation rate and a hypoglycaemia cure
rate of 100%. Moreover, our median surgery time was short,
105min, compared to e.g., 228min by laparoscopy and 406min
by open resections in a recent German study (27), probably
mostly owing to avoidance of multiple biopsies. The relatively
low sensitivity (0.80) of IOUS to detect the lesion was attributed
to the learning process. Our surgery was in all patients guided
by 18F-DOPA-PET/CT as in other recent publications (1, 27, 35).
The 18F-DOPA-PET/CT does not depict the major pancreatic
and the intra-pancreatic common bile ducts (15), and exact same
positioning of the infant during 18F-DOPA-PET/CT and surgery
is regarded crucial for localisation of the focal lesion during
surgery (16). In our experience, IOUS allowed visualization of
the ducts, relevant vessels (e.g., branches from gastroduodenal
artery and portal vein) and localisation of the focal lesion in real
time, thus making the positioning of the patients unimportant.
IOUS as a second imaging after 18F-DOPA-PET/CT in focal CHI
surgery has previously been described as promising (15, 28, 36).
Our preliminary series document for the first time in a patient
cohort the advantage of IOUS to minimize resection of healthy
pancreatic tissue and shorten surgery time as multiple biopsies
become redundant.
Some centers use laparoscopy for pancreatic tail resections
in focal CHI, but with a much longer operating time compared
with the present data. Moreover, the resection may not always
be curative (27). Furthermore, the laparoscopic approach is
dependent on preoperative identification of the focal lesion as
predicted by heterozygous paternal KATP-channel mutations and
18F-DOPA-PET/CT (29, 37, 38). The sensitivity and specificity of
these diagnostic tools do, however, not reach 100% (1, 27, 39–41),
neither in our series (data not shown).
We identified three patients (12%) with early surgery
complications, of which only one was classified above Clavien-
Dindo I. This patient had transient feeding problems with post-
operative delayed gastric emptying. Transient feeding problems
have been reported in many patients with CHI (42).
The rate of surgery-related early complications in CHI varies
substantially (13, 30), and comparisons are hampered by studies
reporting outcome from a mixture of focal and diffuse CHI.
Secondly, the classification (e.g., severity) of complications is
not always reported. Postoperative morbidity is higher in diffuse
CHI due to the extent of resection, but even in focal CHI
high complication rates has been reported (30). We encountered
no severe early or late surgical complications, and the risk of
complications was very low (12% early, 8% late) suggesting that
surgery is safe in patients with focal CHI.
None of our patients developed malabsorption or diabetes,
as frequently seen after near-total pancreatectomy (36). Such
complications should not be expected after tissue-sparing
resection, and we did not observe any of the kind even after
larger pancreatic resections. This included the three patients
with a pancreatico-gastrostomy reconstruction, however,
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with a relatively short follow-up time of 30, 45, and 46
months, respectively. This reconstruction procedure has to our
knowledge never been reported for infants with focal CHI.
One of these patients had a transient pancreatic fistula after
the surgery, requiring no further treatment but pancreatic
drain. In a controlled trial in adults, pancreatico-gastrostomy
reconstructions had a lower rate of pancreatic fistula compared
to pancreatico-jejunostomy reconstructions after pancreatico-
duodenectomy (43). Pancreatico-gastrostomy reconstruction
may be used as an alternative to Roux-en-Y reconstruction in
infants with focal CHI with need of pancreatic head resection
(13), although data are sparse and minimal pancreatic resection
should be the preferred procedure if possible.
In one patient, we identified an ectopic focal lesion in the
duodenal wall very close to themajor duodenal papilla, extending
into the pancreas. Ectopic focal CHI lesions have been described
a few other times with need of repeat surgery up to three
times before identification and cure (1, 23, 44). Our patient
had only one surgery (pancreatic head resection and Roux-
en-Y reconstruction) with four frozen biopsies, a surgery time
of 220min and no early or late complications, giving further
support to the efficiency of a protocol with 18F-DOPA-PET/CT
plus IOUS with few frozen sections and short surgery time, even
for ectopic lesions.
Children with focal CHI are at high risk of
neurodevelopmental impairment (4, 21, 34, 45). Early diagnosis
and sufficient treatment are crucial to avoid this (21). As
disease severity usually correlates with cerebral damage, we
were surprised to find a significant, inverse association between
the maximally recorded glucose infusion rate and neurological
impairment. This finding is, however, in line with an Australian
study (31), where conservatively treated children with later
onset and milder disease more frequently had neurological
deficits than those treated surgically with more severe disease
and earlier onset, although all had become normoglycaemic 35
days after presentation. The less apparent symptoms of milder
hypoglycaemia may cause delay in diagnosis and treatment
and hence result in worse neurological outcome compared to
those presenting with convulsions and loss of consciousness.
Of note, our median disease onset age was 2 days, although
one at the extreme presented on day 30, but had normal
neurodevelopmental outcome.
No association between data related to surgery and
neurodevelopmental impairment was found. We neither found
associations to Apgar score or age at disease onset (symptoms
or diagnosis of hypoglycaemia). Most likely, undertreatment of
severe hypoglycaemia linked to delay in diagnosis and adequate
management at, or in collaboration with, an expert CHI center
was causative (21), but we did not have systematic data from
the referring foreign hospitals to detect a such association in the
present study. Feeding disorder persisted in two (8%), despite
cure of hypoglycaemia at last follow-up, however with a relatively
short follow-up time to 7.8 and 24.2 months’ age. Both patients
had neurodevelopmental impairment and the feeding disorder
was not interpreted as surgery complications. Banerjee et al. (42)
reported persistent feeding problems in 34% after 6 months.
The feeding problems correlated with the disease severity, rather
than medication, nasogastric tube or gastrostomy tube feeding.
The nature of long-lasting or persistent feeding problems in
CHI remains to be studied in further details, although cerebral
damage as a consequence of prolonged, severe hypoglycaemia
seems to be a prominent cause.
Limitations of our study included the retrospective nature
with hospital file data from several centers and countries and the
relatively short median follow-up time of 12.5 months. Strengths
included the relatively large sample size for a rare disease and
detailed data sampling from patient files.
CONCLUSION
Tissue-sparing pancreatic resection of focal CHI was possible in
67% of the patients with few and mild complications and 100%
cure rates for hypoglycaemia. Added on genetics, 18F-DOPA-
PET/CT and intraoperative frozen biopsies, IOUS was a helpful
tool to limit surgical resection of normal pancreatic tissue in
infants with CHI.
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